UCART123
Acute Myeloid Leukemia (AML)
Phase 1Active
Key Facts
About Cellectis
Cellectis is a French-American biotech with 25 years of expertise in gene editing, focused on developing next-generation, 'off-the-shelf' CAR T-cell therapies to address significant unmet needs in oncology. The company's core platform combines its flagship TALEN® technology for ultra-precise genome editing with its PulseAgile electroporation system for efficient cellular engineering. With a robust pipeline of allogeneic CAR T candidates and strategic global partnerships with companies like Allogene, Servier, and AstraZeneca, Cellectis aims to transform cancer treatment by making cell therapies more accessible and scalable.
View full company profileTherapeutic Areas
Other Acute Myeloid Leukemia (AML) Drugs
| Drug | Company | Phase |
|---|---|---|
| NTLA-5001 | Intellia Therapeutics | Phase 1/2 |
| Galinpepimut-S (GPS) | SELLAS Life Sciences | Phase 2/3 |
| SLS009 (GFH009) | SELLAS Life Sciences | Phase 1/2 |
| Iadademstat (ORY-1001) | Oryzon Genomics | Phase 2 |
| MP0533 | Molecular Partners | Phase 1/2 |
| SEL24 (MEN1703) | Selvita | Phase 1/2 |
| Selinexor | Karyopharm Therapeutics | Clinical Trials |
| NEX-20 (azacitidine) | Nanexa AB | Phase 1 |
| SENTI-202 | Senti Biosciences | Phase 1 |
| motixafortide (BL-8040) | BioLineRx | Phase 2a |
| ACD-101 | Advanced Cellular Dynamics | Phase 1 |
| ABD-3001 | Advanced Biodesign | Phase 1 |